Confronto

Linaclotid vs. Pasireotid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

851199-59-2

396091-73-9

Peso molecolare

1526.74 g/mol

1047.21 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Linaclotid	Pasireotid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?: Linaclotid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Pasireotid?: The highest available evidence level is "RCT sull'uomo" for Linaclotid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Pasireotid in Germany and the United States?: Germania: Linaclotid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Linaclotid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Pasireotid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?

Linaclotid is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Pasireotid?

The highest available evidence level is "RCT sull'uomo" for Linaclotid and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Pasireotid in Germany and the United States?

Germania: Linaclotid — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Linaclotid — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.